All Oncology News

With burnout and conference attendance prevalent across the oncology community, oncology professionals strive to enact positive changes.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Gynecologic oncologists share their top data picks from SGO 2026, including ROSELLA, KEYNOTE-B96, NRG-GY019, and more.

A new model explains how genetic information is not just stored but continuously used to keep cells organized and functioning.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses individualized chemotherapy selection and the importance of a "person-first" approach to pancreatic cancer care.

Joshua Lang, MD, MS, discusses the rationale for, and design of, the MEVPRO-1 and MEVPRO-2 studies in mCRPC.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Multipeptide vaccines in combination with BTK inhibitor–based regimens yielded safety and potent T-cell responses in chronic lymphocytic leukemia.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

An sBLA seeking the approval of zenocutuzumab has been submitted to the FDA, and the agent was added to the NCCN guidelines for NRG1-positive cholangiocarcinoma.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

Aaron Gerds, MD, details the rationale behind investigating agents targeting CALR mutations and other novel therapies in myeloproliferative neoplasms.

Alicia Morgans, MD, MPH, and Michael Schweizer, MD, discuss the phase 3 MEVPRO-1 and MEVPRO-2 trials of mevrometostat plus enzalutamide in mCRPC.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

The CSF-1R–targeting monoclonal antibody emactuzumab met key end points in the phase 3 TANGENT study, setting the stage for a BLA submission.

The allogeneic CAR T-cell therapy cema-cel improved MRD negativity rates vs observation as first-line consolidation in LBCL.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

ECOG PS should be evaluated before initiating this agent, as patients with poorer PS may experience shorter life expectancy than reported in trials.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

The FDA has accepted and granted priority review to the BLA seeking the approval of I-DXd in ES-SCLC.

Roswell Park Comprehensive Cancer Center researchers are investigating whether CAR T-cell therapy could target some of the most common autoimmune diseases.